A taron Majalisar Dinkin Duniya na 18th na Ciwon Gastrointestinal, wani bincike na asibiti na kashi na ya nuna cewa anti-PD-L1 immunotherapy hade tare da masu hana MEK na iya magance ciwon daji na metastatic na microsatellite yadda ya kamata.
Babban mai binciken binciken, Johanna Bendell na Cibiyar Cancer ta Sarah Cannon, ya nuna cewa: Ya zuwa yanzu, rigakafin rigakafi ya yi tasiri ne kawai ga marasa lafiya da ke fama da cutar sankarau, kuma wannan nau'in marasa lafiyar na da kashi 5% na yawan mutanen.
Matsakaicin microsatellite mara karko ciwon daji yana da adadi mai yawa na maye gurbi don haka yana amsa anti-PD-1 / PD-L1 immunotherapy. Duk da haka, kusan kashi 95% na marasa lafiya da ke fama da ciwon daji na metastatic suna da kwanciyar hankali na microsatellite. Ya zuwa yanzu, wannan bangare na marasa lafiya da kyar ya amsa maganin rigakafi.
Karatuttukan karatu na farko sun ba da shawarar cewa masu hanawa na MEK na iya sa kumburi ya zama mai saurin kula da rigakafi. Specifica'idar takamaiman na iya zama don ƙara yawan ƙwayoyin ƙwayoyin ƙwayoyin cuta masu aiki (kamar su ƙwayoyin CD8 masu kyau) a cikin ƙari da haɓaka maganganun abubuwan kunnawa na ƙwayoyin cuta.
Sakamakon binciken ya nuna cewa binciken asibiti na Phase I b yayi amfani da mai hana maganin MEK Cobimetinib don kula da marasa lafiya 23 da ke fama da cutar sankarau daidai da tsarin hauhawar kashi. (Q3W), yawancin marasa lafiya na iya jurewa manyan allurai kuma ana kula dasu tare da MG 800 na mai hana PD-L1 mai hanawa Atezolizumab (allurar intravenous, Q2W).
A cikin kulawa na gaba, masu binciken sun lura cewa marasa lafiya 4 (17%) suna da ƙwanƙwasa ƙari aƙalla 30%, kuma marasa lafiya 5 (22%) suna da cutar barga. Lokacin gafartawa mai gudana ya fi watanni 4 ~ 15. Dangane da bayanan yanzu, 2 daga cikin marasa lafiya 4 tare da yin afuwa wani ɓangare sun sami ci gaba mai gafara. Daga cikin marasa lafiyar da ke da gafara, shari'o'in 3 sun kasance zaman lafiyar microsatellite ko rashin kwanciyar hankali na microsatellite, kuma shari'ar 1 ba ta san matsayin microsatellite ba. Daga cikin marasa lafiyar da aka haɗa a cikin binciken, babu shari'ar microsatellites da ba ta da ƙarfi.
Bugu da ƙari, matakin farko na PD-L1 ba ya shafar gafarar cuta, an jure haɗin magunguna sosai, kuma babu wasu munanan abubuwan da suka shafi magani.
Bendell ya karkare da cewa: “Sakamakon binciken ya yi daidai da tunanin hadewar maganin, wanda kuma ya samar da wani kashi 95% na masu fama da cutar sankarau da damar karbar rigakafi.” Mai binciken yana gab da ƙaddamar da nazarin asibiti na lokaci na III, shirin shiga cikin ƙungiyar yana da wahala Don maganin cututtukan cututtukan cikin gida, kwatanta ingancin wannan maganin haɗin gwiwa tare da daidaitattun ƙa'idodi.
